



**Notice Concerning the Execution of a Strategic Collaboration Agreement for the
Expansion of the Clinical iPS Cell Business in the Chinese Market**

July 27, 2026

REPROCELL Inc. (the "Company") hereby announces that it has executed a strategic collaboration agreement with WEIPU Biotechnology Co., Ltd. (hereinafter "WEIPU"), a biotechnology company based in Suzhou, Jiangsu Province, China, aimed at expanding the Company's clinical iPS cell-related business into the Chinese market.

China is one of the world's leading growth markets in the fields of regenerative medicine and cell therapy, with expanding investments in research and development as well as the clinical application of cellular therapeutics. In this market environment, the Company will accelerate the expansion of its clinical iPS cell business in the Chinese market through this collaboration with WEIPU.

Under this collaboration, utilizing WEIPU's sales and customer network in China, the Company will provide clinical cell products, including StemRNA™ clinical iPS cells manufactured using the Company's proprietary RNA reprogramming technology, as well as iPS cell-derived mesenchymal stem cells (iMSCs). Furthermore, the Company will roll out comprehensive solutions to the Chinese market, including the StemEdit clinical gene editing service, which is the Company's proprietary gene modification platform, and manufacturing services for Master Cell Banks (MCB) and Working Cell Banks (WCB), which are essential for the development of cell therapy products.

Additionally, WEIPU will provide biological testing, safety evaluation, and cell bank characterization services. Through synergistic effects with the Company's clinical cell products, a comprehensive service framework will be established to support cell therapy development companies in China from the early development stages through to the clinical development stages.

Chikafumi Yokoyama, President and CEO of the Company, stated the following:
"REPROCELL is committed to providing high-quality clinical cellular raw materials and a highly reliable quality evaluation and documentation system to cell therapy development companies worldwide. China is an important market experiencing rapid growth in the regenerative medicine sector. Through this collaboration with WEIPU, we are extremely pleased to be able to provide global-standard clinical iPS cells and related services to development companies in China. The Company will continue to contribute to the advancement of regenerative medicine while driving business expansion in the global market."

Jenna Yang, CEO of WEIPU, stated the following:
"To respond to the acceleration of regenerative medicine innovation in the Chinese market, through our partnership with REPROCELL, we will build a system that enables development companies to access high-quality stem cell materials and complementary testing services that meet international regulatory requirements."

The impact of this matter on the Company's financial results for the current fiscal year is expected to be minor at this time; however, we believe it will significantly contribute to our further growth and the sustainable enhancement of corporate value over the medium to long term. If any matters requiring disclosure arise in the future, we will promptly announce them.

About WEIPU Biotechnology Co., Ltd.

WEIPU Biotechnology Co., Ltd. is a Contract Research and Testing Organization (CRO) headquartered in Suzhou, Jiangsu Province, China. The company provides biological testing, safety evaluation, and cell bank characterization services for companies in the biopharmaceutical, cell therapy, medical device, and chemical sectors. Equipped with an approximately 8,000 square meter biosafety facility, WEIPU supports customers' research and development and commercialization efforts through testing and evaluation services that comply with the regulatory requirements of China, the United States, and Europe.

URL: <https://www.weipubio-tech.com/en/>